By: Cullen Irwin With the advent of a new administration and the overturning of Chevron comes deregulation initiatives across several industries, creating a slew of implications for drug regulation under the watch of the newly minted Secretary of the Department of Health and Human Services, Robert Kennedy, Jr. (RFK Jr.). RFK Jr.’s confirmation resulted in significant […]
